Sign in

    David Stanton

    Research Analyst at Jefferies

    David Stanton is the Head of Australian Healthcare Research and Managing Director at Jefferies, specializing in equity analysis for leading healthcare companies. He covers prominent firms such as Immutep and has been recognized in multiple investor surveys for top-ranked performance, reflecting his strong success rates and impactful investment calls in the sector. Stanton joined Jefferies in September 2019 after holding senior analyst and leadership roles at ABN Amro/RBS, Nomura, and CLSA in Sydney, where he led regional and global research teams. He holds a Doctor of Medicine degree, an MBA, and serves as a member of NeuRA’s Board, underscoring his deep professional credentials in both finance and healthcare.

    David Stanton's questions to TLPPF leadership

    David Stanton's questions to TLPPF leadership • Q3 2023

    Question

    Asked for a comparison of hematological toxicity rates in the ProstACT SELECT trial versus standard chemotherapy and requested clarification on the full-year R&D spending forecast.

    Answer

    Executives stated that a direct toxicity comparison is difficult without a controlled study but noted the rates are lower than in past studies due to a healthier patient population and appear comparable to competitor data in similar settings. The full-year R&D spend is expected to be around the guided $100-$105 million, which also includes costs for manufacturing scale-up.

    Ask Fintool Equity Research AI